HSIC vs NEOG: fair value comparison
Henry Schein, Inc. and Neogen Corporation · Updated 2026-09-07
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, HSIC currently sits closer to the top of our discount ranking.
| HSIC | NEOG | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $89.81 | $11.90 |
| 12-month range | $63.20–$88.52 | $5.80–$11.90 |
| Sector rank | #70 of 113 Healthcare | #73 of 113 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: HSIC fair value analysis · NEOG fair value analysis